🇺🇸 FDA
Patent

US 11660296

Treatment of chronic cough, breathlessness and dyspnea

granted A61KA61K31/485A61K45/06

Quick answer

US patent 11660296 (Treatment of chronic cough, breathlessness and dyspnea) held by Trevi Therapeutics, Inc. expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Trevi Therapeutics, Inc.
Grant date
Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K31/485, A61K45/06, A61K9/2009, A61K9/2013